Drug Profile
Research programme: respiratory disorder therapeutics - Barcelona Science Park/Laboratorios Almirall
Latest Information Update: 14 Apr 2010
Price :
$50
*
At a glance
- Originator Laboratorios Almirall
- Developer Almirall S.A.; University of Barcelona
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Respiratory tract disorders
Most Recent Events
- 26 Nov 2007 Preclinical trials in Asthma in Spain (unspecified route)
- 26 Nov 2007 Preclinical trials in Chronic obstructive pulmonary disease in Spain (unspecified route)
- 26 Nov 2007 Preclinical trials in Respiratory tract disorders in Spain (unspecified route)